Abstract
The effect of trimethoprim-sulfadiazinea on Schirmer tear test (STT) values was studied in a population of dogs treated with the drug for a variety of medical and postsurgical conditions. The objectives of the study were to determine the incidence of keratoconjunctivitis sicca (KCS) secondary to trimethoprim-sulfadiazine therapy; to determine if such incidence was related to dose, duration, or both; and to identify any other factors that increased patient risk. The package insert accompanying Tribrissen states that "Dogs can tolerate up to ten times the recommended therapeutic dose without exhibiting ill effects." The results of this study indicated a 15.2% (5/33) incidence of KCS in the population of treated dogs.
MeSH terms
-
Animals
-
Anti-Infective Agents / administration & dosage
-
Anti-Infective Agents / adverse effects*
-
Anti-Infective Agents / therapeutic use
-
Body Weight
-
Dog Diseases / chemically induced*
-
Dog Diseases / drug therapy
-
Dog Diseases / metabolism
-
Dogs
-
Drug Combinations
-
Female
-
Incidence
-
Keratoconjunctivitis Sicca / chemically induced
-
Keratoconjunctivitis Sicca / metabolism
-
Keratoconjunctivitis Sicca / veterinary*
-
Male
-
Retrospective Studies
-
Risk Factors
-
Sulfadiazine / administration & dosage
-
Sulfadiazine / adverse effects*
-
Sulfadiazine / therapeutic use
-
Tears / drug effects
-
Tears / metabolism*
-
Trimethoprim / administration & dosage
-
Trimethoprim / adverse effects*
-
Trimethoprim / therapeutic use
Substances
-
Anti-Infective Agents
-
Drug Combinations
-
Sulfadiazine
-
sulfadiazine, trimethoprim drug combination
-
Trimethoprim